Modified Polynucleotides for the production of biologics and proteins associated with human disease

A pharmaceutical composition comprising:

• a plurality of lipid nanoparticles comprising a cationic lipid, a neutral lipid, a cholesterol, and a PEG lipid, wherein the plurality of lipid nanoparticles has a mean particle size of between 80 nm and 160 nm;
• and
• wherein the lipid nanoparticles comprise an mRNA encoding a polypeptide, wherein the mRNA comprises:
• (i) at least one 5′-cap structure;
• (ii) a 5′-UTR;
• (iii) an open reading frame encoding the polypeptide and consisting of nucleotides including uracil, cytosine, adenine, and guanine;
• (iv) a 3′-UTR;
• and
• (v) a poly-A region of least 100 nucleotides in length.